Bergen, Norway, 6 February 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will announce its results for the fourth quarter 2023 on
Wednesday 14 February 2024.

BerGenBio's senior management team will provide a business update at 10:00 am
CET.

The presentation will webcast live. To participate in the webcast please
register in the following link:

BerGenBio Q4 2023 webcast registration
link (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.of
f
ice.com%2Fe%2FjDmiXn9rCD&data=05%7C02%7Crune.skeie%40bergenbio.com%7C71b892a0400
2
4e35831b08dc11204242%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C63840407746043
8
276%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwi
L
CJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=JkXs41rqj%2F85XiPLueKDwCilRQBq%2FC9OuJqjOR%2
B
cdyk%3D&reserved=0)

A recording of the webcast will be available at www.bergenbio.com in the
Investors/Financial Reports
section (https://www.bergenbio.com/investors/financial-reports) shortly
afterwards.

The fourth quarter financial report and presentation will also be made available
on the Company's website in the Investors/Financial Reports
section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CET
the same day.

Warrants

As part of the Rights Issue offering completed in June 2023, BerGenBio issued
Warrants to the subscribers in the offering. The Warrants are tradable under the
ticker BGBIS on the Oslo Stock Exchange up to 8 April 2024. The holders of the
Warrants can exercise the Warrants 1 - 15 April 2024. Additional information
about the Warrants is available on the Company's website in the
Investors/Warrants (https://www.bergenbio.com/investors/investor
-relations/warrants) section.

-End-

Contacts

Martin Olin, CEO BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR
article 17 and section 5-12 of the Norwegian Securities Trading Act.